Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer

Hendrik Tobias Arkenau, Ullrich Graeven, Stephan Kubicka, Axel Grothey, Christina Englisch-Fritz, Albrecht Kretzschmar, Richard Greil, Werner Freier, Thomas Seufferlein, Axel Hinke, Hans Joachim Schmoll, Wolff Schmiegel, Rainer Porschen

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Background: We evaluated the outcome of 140 patients aged ≥ 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin). Patients and Methods: One hundred forty (30%) elderly patients of 476 total patients were identified, and 138 patients received the CAPOX or FUFOX treatment. Results: Overall, treatment was well tolerated, and grade 3/4 toxicities were similar in both groups, with more gastrointestinal side effects in the elderly group but less neurosensory side effects. The response rate (RR) was comparable between both cohorts (49% in elderly patients vs. 52% in patients aged < 70 years). Median progression-free survival (PFS) was 7.7 months for patients aged ≥ 70 years and 7.5 months for patients aged < 70 years (hazard ratio [HR], 1.07; 95% CI, 0.86-1.34). With regard to the chemotherapy regimen, there was no inferiority between FUFOX and CAPOX in patients aged ≥ 70 years (7.9 months vs. 7.6 months). The median overall survival (OS) between FUFOX and CAPOX was comparable in patients aged ≥ 70 years (14.4 months vs. 14.2 months). However, when compared with patients aged < 70 years, the median OS was significantly shorter (18.8 months vs. 14.4 months; P = 0.013; HR, 1.37; 95% CI, 1.07-1.76).This was consistent with our multivariate analysis, which revealed that age ≥ 70 years was a negative factor for OS. Conclusion: Oxaliplatin combined with 5-FU/leucovorin or capecitabine was generally well tolerated in elderly patients. Elderly patients had similar PFS and overall RRs compared with the population aged ≤ 70 years, but the OS was shorter.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalClinical colorectal cancer
Volume7
Issue number1
DOIs
StatePublished - Jan 2008

Keywords

  • CAPOX
  • FOLFOX
  • Fluoropyrimidines

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Arkenau, H. T., Graeven, U., Kubicka, S., Grothey, A., Englisch-Fritz, C., Kretzschmar, A., Greil, R., Freier, W., Seufferlein, T., Hinke, A., Schmoll, H. J., Schmiegel, W., & Porschen, R. (2008). Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clinical colorectal cancer, 7(1), 60-64. https://doi.org/10.3816/CCC.2008.n.009